ClinicalTrials.gg
RecruitingNCT04557891Updated Feb 10, 2026

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

An interventional study of Active LIFUP Treatment and Sham LIFUP Treatment in Generalized Anxiety Disorder, sponsored by University of California, Los Angeles. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Planned enrollment
164th of 234
48 · median 90
Started
2021
with 13 others
No phase
122 of 265
18 open now
Primary completion
2026-12
later than 17 of 52 live
Registered
181st of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 164th largest by planned enrollment of the 234 interventional ones that give a count, is one of 14 that started in 2021, is one of 122 with no phase, reaches primary completion later than 17 of the 52 other live ones, and was the 181st registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused ultrasound stimulation to the amygdala. Anxiety severity will be assessed using standard psychometric scales after each session, and at follow-ups.

Read the detailed description

Anxiety disorders have tremendous disease burden in the United States. Up to 1 in 3 Americans will be diagnosed with an anxiety disorder in their lifetimes. Anxiety treatment is typically consisting of psychotherapy (e.g. cognitive behavioral therapy) and medication management (e.g. benzodiazepines, selective serotonin reuptake inhibitors, etc). With major depressive disorder, rTMS is a suitable alternative treatment for refractory depression, rTMS is not approved for treatment of anxiety, nor can rTMS stimulate deep enough to reach those brain circuits involved in anxiety (e.g. the amygdala). Focused ultrasound is a new treatment modality being developed for several different neuropsychiatric conditions. In this study, the investigators propose to randomize 48 individuals to either active or sham treatment. Each participant will be evaluated to establish a baseline diagnose of generalized anxiety disorder, and then will be reassessed after each treatment session (of which there are four). One week and one month after the last treatment session, the investigators will conduct follow-up evaluations.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • focused ultrasound
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female
  2. Age 18-65
  3. Normal or corrected-to normal vision and hearing
  4. Primary diagnosis of generalized anxiety disorder, moderate/severe per . (HAM-A>17) 4a) The duration of the illness must exceed one year.
  5. Must be medically stable as determined by investigator
  6. Patient must have attempted and failed treatment with at least 2 SSRI and 1 augmentation
  7. History of rTMS is permitted, but not required.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary anxiety disorder other than GAD 1a) Affective disorders such as unipolar or bipolar depression are permitted as long as GAD is primary
  2. Current use of any non-prescribed psychoactive medications or drugs (aside from medications for treatment of GAD)
  3. to enter the MRI environment
  4. Pregnancy (or suspected/possible pregnancy or plan to become pregnant in the short-term)
  5. Inability to adhere to treatment schedule
  6. Initiation of new anxiolytic treatment at the time of study randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Low Intensity Focused Ultrasound

    Device: Low Intensity Focused Ultrasound Device Low Intensity Focused Ultrasound Pulsation (LIFUP) of amygdala (a key area for anxiety) will be performed during two sessions. The proposed experiment will involve behavioral (e.g. HAM-A) and paramedical (i.e., MRI/fMRI) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group will well blinded.

    Device: Active LIFUP Treatment

  • Sham comparator
    Sham

    Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group will well blinded.

    Device: Sham LIFUP Treatment

Interventions

  • DeviceActive LIFUP Treatment

    8 LIFUP Treatments

    Also known as: BX Pulsar 1002

  • DeviceSham LIFUP Treatment

    8 sham LIFUP treatments

06

What researchers measure

Primary outcomes

  1. Hamilton Anxiety Rating Scale (HAM-A)

    HAM-A is a rating scale for measuring the severity of anxiety symptoms.

    Time frame: 1 week after the fourth LIFUP treatment

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 65 months is above that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 22, 2020
StartActual
Jul 26, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04557891
Responsible party
Margaret Distler, MD, PhD (Health Sciences Assistant Clinical Professor, University of California, Los Angeles) — Principal investigator
First posted
Sep 22, 2020
Start date
Jul 26, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Margaret G Distler, MD,PhD
Contact
mdistler@mednet.ucla.edu
(310) 794-1553
Andrew Bishay, BS
Contact
abishay@mednet.ucla.edu
4243719869
Margaret G Distler, MD,PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion